Denali Therapeutics announces primary analysis of Phase 1/2 study in MPS II
Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for ...
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...
Cure Today2 天
FDA-Approved Calquence Combo Is First and Only of Its Kind in MCL
Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...
Treatment for Guillain-Barre Syndrome (GBS) included under Ayushman Bharat Arogya Karnataka
Suvarna Arogya Suraksha Trust (SAST), the nodal agency implementing the health schemes of Karnataka, has been directed to ...
clinicaladvisor.com11 天
Grafapex Approved as Part of Conditioning Regimen for HSCT in AML, MDS Patients
The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan) for injection with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...
Medpage Today on MSN17 天
FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen
The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia ...
BioSpace24 天
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo ...
Dose interruptions due to an adverse reaction occurred in 44% of patients. The adverse reactions leading to dose interruption in >2 patients were viral infection, infection (pathogen unspecified), ...
Yahoo Finance26 天
Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue ...
DURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered ...